BACKGROUND & AIMS: Barrett's esophagus (BE) increases risk for esophageal adenocarcinoma, but it is not clear how it affects risk for other cancers or overall mortality. We analyzed data from a population-based cohort of subjects with BE. METHODS: The Netherlands Cohort Study was initiated in 1986 and included 120,852 participants (55-69 years old at baseline). Until December 2002, 626 incident cases of BE (excluding nonintestinal metaplasia) were identified by record linkage with the nationwide Pathology Registry. This cohort was followed for a median period of 5.7 years; data on cancer and mortality were obtained from record linkage to the Netherlands Cancer Registry and Statistics Netherlands. The expected number of cases was calculated using national cancer incidence and mortality data. RESULTS: In the BE cohort, 13 individuals developed esophageal cancer and 5 developed gastric cancer. The ratio of observed:expected (O:E) incidence of esophageal and gastric cancer was 10.0 (95% confidence interval [CI], 5.3-17.1) and 1.8 (95% CI, 0.6-4.2), respectively. Total cancer incidence (excluding esophageal and gastric cancer) increased in the BE cohort, although not by a statistically significant amount (O:E, 1.3; 95% CI, 1.0-1.6). Of cancer subtypes, incidences of small intestinal and pancreatic cancer increased in subjects with BE, but not by a statistically significant amount, after exclusion of data from the first 6 months of follow-up. During the follow-up period, 225 individuals with BE died. Mortality from all causes (excluding esophageal and gastric cancer) was not increased among subjects with BE (O:E, 1.0; 95% CI, 0.9-1.2), nor was mortality from specific causes of death. CONCLUSIONS: The incidence of esophageal cancer was increased in a population-based cohort of subjects with BE. However, when esophageal and gastric cancers were excluded, total cancer incidence and overall mortality were not increased among subjects with BE.
BACKGROUND & AIMS:Barrett's esophagus (BE) increases risk for esophageal adenocarcinoma, but it is not clear how it affects risk for other cancers or overall mortality. We analyzed data from a population-based cohort of subjects with BE. METHODS: The Netherlands Cohort Study was initiated in 1986 and included 120,852 participants (55-69 years old at baseline). Until December 2002, 626 incident cases of BE (excluding nonintestinal metaplasia) were identified by record linkage with the nationwide Pathology Registry. This cohort was followed for a median period of 5.7 years; data on cancer and mortality were obtained from record linkage to the Netherlands Cancer Registry and Statistics Netherlands. The expected number of cases was calculated using national cancer incidence and mortality data. RESULTS: In the BE cohort, 13 individuals developed esophageal cancer and 5 developed gastric cancer. The ratio of observed:expected (O:E) incidence of esophageal and gastric cancer was 10.0 (95% confidence interval [CI], 5.3-17.1) and 1.8 (95% CI, 0.6-4.2), respectively. Total cancer incidence (excluding esophageal and gastric cancer) increased in the BE cohort, although not by a statistically significant amount (O:E, 1.3; 95% CI, 1.0-1.6). Of cancer subtypes, incidences of small intestinal and pancreatic cancer increased in subjects with BE, but not by a statistically significant amount, after exclusion of data from the first 6 months of follow-up. During the follow-up period, 225 individuals with BE died. Mortality from all causes (excluding esophageal and gastric cancer) was not increased among subjects with BE (O:E, 1.0; 95% CI, 0.9-1.2), nor was mortality from specific causes of death. CONCLUSIONS: The incidence of esophageal cancer was increased in a population-based cohort of subjects with BE. However, when esophageal and gastric cancers were excluded, total cancer incidence and overall mortality were not increased among subjects with BE.
Authors: B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill Journal: United European Gastroenterol J Date: 2016-02-19 Impact factor: 4.623
Authors: Michael B Cook; Sally B Coburn; Jameson R Lam; Philip R Taylor; Jennifer L Schneider; Douglas A Corley Journal: Gut Date: 2017-01-04 Impact factor: 23.059
Authors: W Asher Wolf; Sarina Pasricha; Cary Cotton; Nan Li; George Triadafilopoulos; V Raman Muthusamy; Gary W Chmielewski; F Scott Corbett; Daniel S Camara; Charles J Lightdale; Herbert Wolfsen; Kenneth J Chang; Bergein F Overholt; Ron E Pruitt; Atilla Ertan; Srinadh Komanduri; Anthony Infantolino; Richard I Rothstein; Nicholas J Shaheen Journal: Gastroenterology Date: 2015-08-29 Impact factor: 22.682
Authors: Gary W Falk; Navtej S Buttar; Nathan R Foster; Katie L Allen Ziegler; Catherine J Demars; Yvonne Romero; Norman E Marcon; Thomas Schnell; Douglas A Corley; Prateek Sharma; Marcia R Cruz-Correa; Chin Hur; David E Fleischer; Amitabh Chak; Kenneth R Devault; David S Weinberg; Gary Della'Zanna; Ellen Richmond; Thomas C Smyrk; Sumithra J Mandrekar; Paul J Limburg Journal: Gastroenterology Date: 2012-07-11 Impact factor: 22.682